Strategic Plan Metrics - Research

Co-develop solutions to the critical issues facing 21st century Nevada and raise the overall research profile

Inventions / Patents

FY 2013 FY 2014 FY 2015 FY 2016 FY 2017 5YR Avg
Innovation / Invention Disclosures191629171720.4
New Patent Applications Filed1051516710.6
U.S. Patents Issued1613119711.2
Exclusive Licenses / Options-112-0.8
Non-Exclusive Licenses / Options141262.8

NevadaNanotech Systems, Inc. develops and manufactures MEMS-based small, low cost sensors that can operate unattended for a diverse array of commercial, governmental, and residential applications. Founded in 2004, NevadaNano is UNR’s first spinout company created to commercialize a unique sensor technology created at the university. Products include sensors to detect micromolar amounts of vapors and particles given off, for example, by bioweapons, illicit drugs, human respiration, and a wide variety of other sources making the sensors ideal for use in many realms, including residential IoT applications.

Strykagen, Inc. is a UNR spinout company founded by Drs. Dean Burkin and Ryan Wuebbles in the School of Medicine. Strykagen’s mission is to develop treatments to reduce and even cure the burden of muscular dystrophy and other rare muscle-wasting diseases. Strykagen has licensed a substantial patent portfolio from the university and is poised to begin clinical trials on one therapeutic within the next two years.

Researchers at UNR’s School of Medicine have developed a number of diagnostic tests for infectious diseases. These tests are all inexpensive, point of care tests that can be used to rapidly diagnose diseases that are otherwise difficult to diagnose and/or represent major health threats, particularly for the armed forces or that are related to biothreats. For example, a test for melioidosis, a difficult to diagnose disease caused by Burkholderia pseudomallei that affects people and armed forces in Asia. The disease is easily misdiagnosed and if treated incorrectly, has a 70% mortality rate. This test has been licensed nonexclusively to InBIOS International, a company actively working with the US Department of Defense to develop and make the test widely available. InBIOS is planning to seek FDA approval for clinical use in the coming year.

Another example is a rapid, simple point-of care diagnostic test that can detect anthrax infection within fifteen minutes has been licensed by InBIOS. InBIOS is working with the Biomedical Advanced Research and Development Authority (BARDA), a division within the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR). BARDA and InBIOS are engaging in testing that can lead to FDA approval for clinical use.

The World Health Organization (WHO) has added screening and diagnosis of cryptococcal meningitis in people living with advanced HIV disease to its list of essential in vitro diagnostic tests that should be available in primary healthcare settings, hospitals, and reference labs for routine patient care. This test was developed at UNR and licensed to ImmunoMycologics.

UNR conducts extensive research regarding conversion of wet biowaste such as that produced in large cattle, pig, and chicken operations to something that can be used to create heat and power. Dr. Chuck Coronella's research has given rise to a number of patents and patent applications that deal with biowaste conversion in a manner that is inexpensive, energy-efficient, and substantially more effective than current waste disposal techniques. The process is fast, inexpensive, and can be used on individual farms or for large-scale waste processing and disposal. Active commercialization efforts are currently underway.

Innovation / Invention Disclosures
includes the number of disclosures, no matter how comprehensive, that are submitted during the reported fiscal years and are counted as received by the institution or its designated Intellectual Property Management Office.
New Patent Applications Filed
Includes The First Filing Of The Patentable Subject Matter. New Patent Applications Filed Do Not Include Continuations, Divisionals, Or Reissues, And Typically Do Not Include Cips. When A U.S. Provisional Application Is Converted In To A U.S. Utility Application, Then That Corresponding U.S. Utility Application Is Not Be Counted As New.
U.S. Patents Issued
Includes The Number Of U.S. Patents Issued Or Reissued To An Institution In The Reported Fiscal Years. Certificates Of Plant Variety Protection Issued By The U.S.D.A., If Any, Are Included.
Include The Total Number Of License Or Option Agreements That Were Executed During The Reported Fiscal Years Indicated For All Technologies. Each Agreement, Exclusive Or Non­Exclusive, Is Counted Separately.